Friday, April 25, 2025 9:44:21 PM
Mani,
I've never seen an update on how discussions with a regulator were going in any product under consideration unless something official came from the regulator that must be revealed. I've seen many products where the regulator did demand additional trials and the product was approved after those trials, but in every such case the decision requiring more came rather quickly. I believe that they're considering many things, and rather than approval being delayed, the company may be providing more to get consideration of a tumor agnostic label.
If six months ago the company were told, we'll approve you for GBM, or we'll consider more evidence that a tumor agnostic label, if you're willing to delay approval. What would you do?
I certainly don't know this was the case, and frankly we'll never learn what's caused this to take so long, but I believe anything is possible. It may be a completely different effort, but I also believe they're working diligently on gaining approval of the EDEN in the UK.
Gary
I've never seen an update on how discussions with a regulator were going in any product under consideration unless something official came from the regulator that must be revealed. I've seen many products where the regulator did demand additional trials and the product was approved after those trials, but in every such case the decision requiring more came rather quickly. I believe that they're considering many things, and rather than approval being delayed, the company may be providing more to get consideration of a tumor agnostic label.
If six months ago the company were told, we'll approve you for GBM, or we'll consider more evidence that a tumor agnostic label, if you're willing to delay approval. What would you do?
I certainly don't know this was the case, and frankly we'll never learn what's caused this to take so long, but I believe anything is possible. It may be a completely different effort, but I also believe they're working diligently on gaining approval of the EDEN in the UK.
Gary
Bullish
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
